Stay updated on PATHWay Study: Adjuvant Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page.

Latest updates to the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page
- Check2 days agoChange DetectedThe page revision/version has been incremented from v3.5.2 to v3.5.3, indicating a backend or release update without altering the displayed study information.SummaryDifference0.1%

- Check9 days agoChange DetectedRevision v3.5.2 was added and revision v3.5.0 was removed.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedSite revision updated: added Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check46 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3; no visible changes to study content.SummaryDifference0.1%

- Check74 days agoChange DetectedThe page now displays a new revision label 'Revision: v3.4.2', and the prior general funding/operating status notice was removed. These are administrative changes that do not affect the study content, eligibility criteria, or outcomes.SummaryDifference0.5%

- Check81 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and the NIH Clinical Center's status, with guidance to visit cc.nih.gov and opm.gov; updated the revision tag to v3.4.1 (replacing v3.4.0).SummaryDifference0.5%

Stay in the know with updates to PATHWay Study: Adjuvant Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page.